Luminor®紫杉醇药物涂层球囊治疗腘动脉粥样硬化病变的疗效与一年结局
前瞻性收集2019年1月至6月33例腘动脉粥样硬化病变患者,其中85%为严重肢体缺血、64%为慢性腘动脉闭塞,均接受Luminor®药物涂层球囊治疗。技术成功率达100%,围手术期死亡1例(3%),随访见ABI显著升高,估计24个月生存率97%、一期通畅率96.9%、二期通畅率100%、免于再狭窄率93.8%。
要点
- Luminor®药物涂层球囊治疗腘动脉病变技术成功率达100%,围手术期死亡1例(3%)。
- 随访ABI由0.57(IQR 0.41-0.47)升至0.69(IQR 0.50-0.67),差异有统计学意义(P<0.01)。
- 估计24个月一期通畅率96.9%、免于再狭窄率93.8%,但样本量小、需更长期研究验证耐久性。
核心结论
- Luminor®药物涂层球囊治疗腘动脉粥样硬化病变在本前瞻性研究中安全有效,但需更大样本和更长随访评估其耐久性。
研究设计与样本
- 单中心前瞻性研究,2019年1月至6月连续收集33例腘动脉粥样硬化病变患者。
- 纳入标准为严重肢体缺血或严重跛行合并腘动脉狭窄>50%。
- 中位随访22.43±4个月(均值21.58,IQR 20-24)。
主要发现
- 33例中28例(85%)为严重肢体缺血,21例(64%)为慢性腘动脉闭塞,平均术前流出道评分5.39(范围0-10,SD 3)。
- 技术成功率为100%,围手术期死亡1例(3%),围手术期并发症2例(6%)。
- 随访期间症状复发2例,大截肢1例(3%)、小截肢2例(6%)。
- ABI由0.57(IQR 0.41-0.47)升至0.69(IQR 0.50-0.67),P<0.01。
- 估计24个月生存率97%、一期通畅率96.9%、二期通畅率100%、免于再狭窄率93.8%。
关键数值与推荐
- 纳入标准:严重肢体缺血或严重跛行伴腘动脉狭窄>50%。
- 评价指标包括技术成功、围手术期及晚期死亡与并发症、症状复发、截肢、ABI、生存率、一期与二期通畅率及免于再狭窄率。
临床怎么用
- 对腘动脉粥样硬化病变(含严重肢体缺血及慢性闭塞)可考虑使用Luminor®药物涂层球囊,但需结合本中心经验与患者选择。
- 术后应规律随访ABI与影像,监测症状复发、再狭窄及截肢风险。
局限性
- 单中心小样本(33例),随访时间有限,缺乏对照组,结论外推需谨慎。
- 作者指出需更大规模、更长随访研究评估器械耐久性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Reporting outcomes with a new generation paclitaxel eluting balloon (Luminor®; iVascular, Vascular, S.L.U., Barcelona, Spain) in the popliteal district. Endovascular treatment of popliteal artery atherosclerotic disease is still debated without definitive evidences. METHODS: From January to June 2019, patients' data presenting popliteal artery atherosclerotic diseases and treated with the Luminor® (iVascular) drug eluting balloon (DEB) were prospectively collected. Critical limb ischemia (CLI) or severe claudication associated with popliteal artery stenosis >50% were the inclusion criteria. Measured outcomes were technical success, early and late results; including mortality, morbidity, symptoms recurrence, amputation, ankle-brachial index (ABI), survival, primary patency, secondary patency, freedom from restenosis. Median follow-up was 22.43 ± 4 (mean:21.58; IQR:20-24) months. RESULTS: Of the 33 included patients, 28 (85%) were diagnosed with CLI, with a mean preoperative run-off score of 5.39 (r:0-10; SD:3) and a chronic popliteal occlusion in 21 (64%). Technical success was achieved in all cases. Perioperative mortality was observed in 1 (3%) patient and perioperative complications in 2 (6%). During the follow-up were reported 2 symptoms recurrence; a significant ABI increase (0.57; IQR:0.41-0.47 vs. 0.69; IQR:0.50-0.67; P < 0.01); 1 (3%) major and 2 (6%) minor amputations. Estimated 24 months survival, primary patency, secondary patency, and freedom from restenosis were 97%, 96.9%, 100%, and 93.8% respectively. CONCLUSIONS: In this prospective study, the use of the Luminor® (iVascular) was safe and effective in addressing atherosclerotic popliteal artery lesions. Larger studies with longer term-outcomes are required to assess the durability of this device in the popliteal artery.
引用
- Pecoraro F, Dinoto E, Pakeliani D, et al. Efficacy and one-year outcomes of Luminor® paclitaxel-coated drug-eluting balloon in the treatment of popliteal artery atherosclerosis lesions. Ann Vasc Surg. 2021. PMID: 33951533. doi:10.1016/j.avsg.2021.04.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。